Subfield · Hepatology
Most cited papers in Hepatology
What are the most cited papers in Hepatology?
The most cited paper in Hepatology is "Sorafenib in Advanced Hepatocellular Carcinoma" (Josep Maria Llovet et al., 2008), with 13,116 citations. Next come "Design and validation of a histological scoring system for nonalcoholic fatty liver disease†" (10,904) and "Management of Hepatocellular Carcinoma: An Update Δσ" (8,176).
Showing 50 of 96 papers. Every paper with more than 2,705 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Sorafenib in Advanced Hepatocellular Carcinoma Josep Maria Llovet et al. · New England Journal of Medicine | 23 Jul 2008 | 13,116 |
| 2 | Design and validation of a histological scoring system for nonalcoholic fatty liver disease† David Erwin Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology | 24 May 2005 | 10,904 |
| 3 | Management of Hepatocellular Carcinoma: An Update Δσ Jordi Bruix, Morris Sherman · Hepatology | 19 Jan 2011 | 8,176 |
| 4 | Transection of the oesophagus for bleeding oesophageal varices R. N. H. Pugh, I M Murray-Lyon, J L Dawson et al. · British journal of surgery | Aug 1973 | 8,027 |
| 5 | Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Richard S. Finn et al. · New England Journal of Medicine | 13 May 2020 | 7,547 |
| 6 | The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases Naga Chalasani, Zobair M. Younossi, Joel E. Lavine et al. · Hepatology | 17 Jul 2017 | 7,419 |
| 7 | Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche Toshiro Sato, Robert G.J. Vries, Hugo J.G. Snippert et al. · Nature | 29 Mar 2009 | 7,361 |
| 8 | Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis Vincenzo Mazzaferro, Enrico Regalia, Roberto Doci et al. · New England Journal of Medicine | 14 Mar 1996 | 7,221 |
| 9 | Changes of Intestinal Functions in Liver Cirrhosis Hiroshi Fukui, Reiner Wiest · Inflammatory Intestinal Diseases | 2016 | 6,814 |
| 10 | Hepatocellular carcinoma Josep Maria Llovet, Robin Kate Kelley, Augusto García Villanueva et al. · Nature Reviews Disease Primers | 21 Jan 2021 | 6,733 |
| 11 | Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection Michael Fried, Mitchell L. Shiffman, K. Rajender Reddy et al. · New England Journal of Medicine | 25 Sep 2002 | 6,410 |
| 12 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Michael Peter Manns, John G. McHutchison, Stuart C. Gordon et al. · The Lancet | Sep 2001 | 6,056 |
| 13 | Management of Hepatocellular Carcinoma * Jordi Bruix, Morris Sherman · Hepatology | 26 Oct 2005 | 5,904 |
| 14 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Ann‐Lii Cheng et al. · The Lancet Oncology | 18 Dec 2008 | 5,881 |
| 15 | Hepatocellular carcinoma Alejandro Forner, María Reig, Jordi Bruix · The Lancet | 4 Jan 2018 | 5,713 |
| 16 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Masatoshi Kudo et al. · The Lancet | Mar 2018 | 5,578 |
| 17 | EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection Pietro Lampertico, Kosh Agarwal, Thomas Berg et al. · Journal of Hepatology | 18 Apr 2017 | 5,528 |
| 18 | Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis Hashem B. El‐Serag, K. Lenhard Rudolph · Gastroenterology | Jun 2007 | 5,483 |
| 19 | Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma Severin Gloor, Kai Oliver Jensen, Stefan Breitenstein et al. · Case Reports in Gastroenterology | 21 Mar 2017 | 5,376 |
| 20 | Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention Zobair M. Younossi, Quentin Mark Anstee, Milena Marietti et al. · Nature Reviews Gastroenterology & Hepatology | 20 Sep 2017 | 5,362 |
| 21 | Chapter 4 Preparation of Isolated Rat Liver Cells Per O. Seglen · Methods in cell biology | 1976 | 5,348 |
| 22 | Histological grading and staging of chronic hepatitis Kamal G. Ishak, Amélia Baptista, Leonardo Bianchi et al. · Journal of Hepatology | Jun 1995 | 5,081 |
| 23 | A Model to Predict Survival in Patients With End–Stage Liver Disease Patrick S. Kamath, Russell H. Wiesner, Michael Malinchoc et al. · Hepatology | Feb 2001 | 5,005 |
| 24 | Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡ Richard K. Sterling, Eduardo Lissen, Nathan Clumeck et al. · Hepatology | 25 May 2006 | 4,995 |
| 25 | The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets Gisa Gerold, Thomas Pietschmann · Digestive Diseases | 2014 | 4,864 |
| 26 | Liver fibrosis Ramon A. Bataller, David A. Brenner · Journal of Clinical Investigation | Feb 2005 | 4,815 |
| 27 | Hepatocellular Carcinoma Augusto García Villanueva · New England Journal of Medicine | 10 Apr 2019 | 4,745 |
| 28 | Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases Jorge A. Marrero, Laura Kulik, Claude B. Sirlin et al. · Hepatology | 6 Apr 2018 | 4,682 |
| 29 | A global view of hepatocellular carcinoma: trends, risk, prevention and management Ju Dong Yang, Pierre L. Hainaut, Gregory James Gores et al. · Nature Reviews Gastroenterology & Hepatology | 22 Aug 2019 | 4,459 |
| 30 | A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C Chun‐Tao Wai, Joel K. Greenson, Robert J. Fontana et al. · Hepatology | 25 Jul 2003 | 4,422 |
| 31 | Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance Norah A. Terrault, Anna S. Lok, Brian J. McMahon et al. · Hepatology | 5 Feb 2018 | 4,390 |
| 32 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Anthony B. El-Khoueiry et al. · The Lancet | 20 Apr 2017 | 4,384 |
| 33 | Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma Riccardo Antonio Lencioni, Josep Maria Llovet · Seminars in Liver Disease | Feb 2010 | 4,376 |
| 34 | BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update María Reig, Alejandro Forner, Jordi Rimola et al. · Journal of Hepatology | 19 Nov 2021 | 4,345 |
| 35 | AASLD guidelines for the treatment of hepatocellular carcinoma Julie K. Heimbach, Laura Kulik, Richard S. Finn et al. · Hepatology | 28 Jan 2017 | 4,204 |
| 36 | A human colon cancer cell capable of initiating tumour growth in immunodeficient mice Catherine Adell O'Brien, Aaron F. Pollett, Steven Gallinger et al. · Nature | 19 Nov 2006 | 4,107 |
| 37 | Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference Jordi Bruix, Morris Sherman, Josep Maria Llovet et al. · Journal of Hepatology | Sep 2001 | 4,098 |
| 38 | An Algorithm for the Grading of Activity in Chronic Hepatitis C Pierre Bédossa, Thierry Poynard · Hepatology | Aug 1996 | 4,058 |
| 39 | Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions Elizabeth M. Brunt, Christine G. Janney, Adrian M. Di Bisceglie et al. · The American Journal of Gastroenterology | Sep 1999 | 3,891 |
| 40 | Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium Toshiro Sato, Daniel E. Stange, Marc Ferrante et al. · Gastroenterology | 3 Sep 2011 | 3,882 |
| 41 | The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Naga Chalasani, Zobair M. Younossi, Joel E. Lavine et al. · Hepatology | 6 Apr 2012 | 3,843 |
| 42 | Burden of liver diseases in the world Sumeet K. Asrani, Harshad C. Devarbhavi, John E. Eaton et al. · Journal of Hepatology | 25 Sep 2018 | 3,840 |
| 43 | Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification Josep Maria Llovet, Concepció Brú, Jordi Bruix · Seminars in Liver Disease | 1999 | 3,836 |
| 44 | Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer Yuman Fong, Joseph G. Fortner, Ruth L. Sun et al. · Annals of Surgery | Sep 1999 | 3,738 |
| 45 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Jordi Bruix et al. · The Lancet | 5 Dec 2016 | 3,732 |
| 46 | Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity Jeffrey D. Browning, Lidia S. Szczepaniak, Robert L. Dobbins et al. · Hepatology | 24 Nov 2004 | 3,698 |
| 47 | Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis† Robert G. Knodell, Kamal G. Ishak, William C. Black et al. · Hepatology | Sep 1981 | 3,575 |
| 48 | Hepatocellular Carcinoma Hashem B. El‐Serag · New England Journal of Medicine | 21 Sep 2011 | 3,545 |
| 49 | Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Dongliang Ge, Jacques Fellay, Alexander J. V. Thompson et al. · Nature | 16 Aug 2009 | 3,535 |
| 50 | Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Josep Maria Llovet, María Isabel Real, Xavier Montañá et al. · The Lancet | May 2002 | 3,526 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.